Clinical trial
A Phase I Trial of Lenalidomide, Umbralisib and Ublituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT04635683 is registered in ClinicalTrials.gov with Yazeed Sawalha as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial of Lenalidomide, Umbralisib and Ublituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
- Lead sponsor
- Yazeed Sawalha
- Phase
- Phase 1
- Overall status
- Withdrawn
- Start date
- September 30, 2022
- Completion date
- December 31, 2024
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent b-cell non-hodgkin lymphoma, recurrent extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, recurrent follicular lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3a follicular lymphoma, recurrent lymphoplasmacytic lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent nodal marginal zone lymphoma, recurrent splenic marginal zone lymphoma, recurrent waldenstrom macroglobulinemia, refractory b-cell non-hodgkin lymphoma, refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, refractory follicular lymphoma, refractory grade 1 follicular lymphoma, refractory grade 2 follicular lymphoma, refractory grade 3a follicular lymphoma, refractory lymphoplasmacytic lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory nodal marginal zone lymphoma, refractory splenic marginal zone lymphoma, refractory waldenstrom macroglobulinemia